Dynavax Technologies Corporation (DVAX) Financial Ratios
23 years of historical data (2002–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
503.23
↑+207% vs avg
5yr avg: 163.77
30Y Low5.7·High12.0
P/FCF
↑
30.24
↑+48% vs avg
5yr avg: 20.39
30Y Low5.7·High28.9
P/B Ratio
↓
3.46
↓-30% vs avg
5yr avg: 4.91
30Y Low1.5·High49.7
ROE
↑
4.5%
↓+124% vs avg
5yr avg: -18.7%
30Y Low-428%·High73%
Debt/EBITDA
↑
64.74
↑+188% vs avg
5yr avg: 22.48
30Y Low0.9·High1.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DVAX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Dynavax Technologies Corporation trades at 77.5x earnings, 148% above its 5-year average of 31.3x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 250%. On a free-cash-flow basis, the stock trades at 30.2x P/FCF, 48% above the 5-year average of 20.4x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.7B | $1.8B | $1.6B | $1.9B | $448M | $412M | $571M | $984M | $152M | $794M |
| Enterprise Value | $2.0B | $1.9B | $1.9B | $1.7B | $1.7B | $634M | $589M | $622M | $957M | $128M | $750M |
| P/E Ratio → | 77.50 | 63.85 | — | 5.40 | 24.68 | — | — | — | — | — | — |
| P/S Ratio | 6.56 | 6.14 | 7.75 | 2.22 | 4.26 | 9.63 | 11.70 | 69.60 | 3008.76 | 13.77 | 196.15 |
| P/B Ratio | 3.46 | 2.85 | 2.89 | 2.76 | 8.42 | 7.64 | 49.70 | 9.05 | 4.93 | 1.71 | 4.25 |
| P/FCF | 30.24 | 28.30 | 18.66 | 28.87 | 5.74 | — | — | — | — | — | — |
| P/OCF | 27.35 | 25.60 | 17.90 | 25.58 | 5.58 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DVAX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Dynavax Technologies Corporation's enterprise value stands at 503.2x EBITDA, 207% above its 5-year average of 163.8x. The Healthcare sector median is 14.2x, placing the stock at a 3440% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.71 | 8.21 | 2.30 | 3.85 | 13.62 | 16.71 | 75.89 | 2927.46 | 11.57 | 185.08 |
| EV / EBITDA | 503.23 | 473.62 | — | 5.72 | 11.96 | — | — | — | — | — | — |
| EV / EBIT | — | 49.44 | 797.62 | 5.52 | 19.08 | — | — | — | — | — | — |
| EV / FCF | — | 30.94 | 19.76 | 29.88 | 5.19 | — | — | — | — | — | — |
DVAX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Dynavax Technologies Corporation earns an operating margin of -1.5%. Operating margins have compressed from 39.2% to -1.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 4.5% is modest.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.2% | 82.2% | 78.4% | 63.7% | 60.5% | 70.1% | 44.9% | -165.9% | -265.1% | 100.0% | 100.0% |
| Operating Margin | -1.5% | -1.5% | -15.9% | 39.2% | 30.6% | -161.6% | -382.9% | -1870.2% | -29359.3% | -1002.5% | -2594.4% |
| Net Profit Margin | 9.9% | 9.9% | -2.8% | 40.6% | 17.5% | -161.6% | -433.3% | -1938.3% | -29099.1% | -1018.2% | -2636.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 4.5% | -1.1% | 73.0% | 54.6% | -224.7% | -427.7% | -121.0% | -65.9% | -81.4% | -74.3% |
| ROA | 2.8% | 2.8% | -0.6% | 29.0% | 11.0% | -23.8% | -62.3% | -74.0% | -57.9% | -68.9% | -60.2% |
| ROIC | -0.4% | -0.4% | -4.1% | 62.5% | 70.0% | -26.3% | -67.5% | -80.0% | -60.5% | -80.2% | -77.7% |
| ROCE | -0.4% | -0.4% | -4.2% | 43.0% | 35.5% | -30.0% | -67.6% | -82.2% | -66.2% | -79.8% | -68.7% |
DVAX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Dynavax Technologies Corporation carries a Debt/EBITDA ratio of 64.7x, which is highly leveraged (1914% above the sector average of 3.2x). Net debt stands at $159M ($254M total debt minus $96M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.43 | 0.43 | 0.41 | 0.44 | 1.16 | 3.71 | 26.11 | 1.60 | — | — | — |
| Debt / EBITDA | 64.74 | 64.74 | — | 0.89 | 1.82 | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.27 | 0.17 | 0.10 | -0.80 | 3.17 | 21.30 | 0.82 | -0.13 | -0.27 | -0.24 |
| Net Debt / EBITDA | 40.34 | 40.34 | — | 0.19 | -1.26 | — | — | — | — | — | — |
| Debt / FCF | — | 2.64 | 1.11 | 1.01 | -0.55 | — | — | — | — | — | — |
| Interest Coverage | -0.61 | -0.61 | -5.48 | 42.12 | 12.03 | -3.95 | -7.94 | -16.42 | — | — | -183.69 |
DVAX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Dynavax Technologies Corporation's current ratio of 10.80x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 9.91x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 6.11x to 10.80x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.80 | 10.80 | 13.81 | 6.11 | 1.75 | 3.75 | 3.93 | 4.33 | 10.32 | 4.06 | 6.81 |
| Quick Ratio | 9.91 | 9.91 | 12.96 | 5.71 | 1.64 | 2.92 | 3.15 | 3.83 | 10.30 | 4.47 | 6.95 |
| Cash Ratio | 9.08 | 9.08 | 11.94 | 4.16 | 0.98 | 2.13 | 2.85 | 3.83 | 10.32 | 4.06 | 6.81 |
| Asset Turnover | — | 0.28 | 0.23 | 0.73 | 0.42 | 0.13 | 0.13 | 0.04 | 0.00 | 0.10 | 0.02 |
| Inventory Turnover | 0.71 | 0.71 | 0.94 | 4.41 | 2.83 | 0.22 | 0.47 | 1.15 | 3.83 | — | — |
| Days Sales Outstanding | — | 61.75 | 69.98 | 74.50 | 109.49 | 177.68 | 92.09 | 164.91 | 953.24 | 44.36 | 125.63 |
DVAX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Dynavax Technologies Corporation returns 5.5% to shareholders annually primarily through share buybacks. The earnings yield of 1.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 1.6% | — | 18.5% | 4.1% | — | — | — | — | — | — |
| FCF Yield | 3.3% | 3.5% | 5.4% | 3.5% | 17.4% | — | — | — | — | — | — |
| Buyback Yield | 5.5% | 5.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% |
| Total Shareholder Yield | 5.5% | 5.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% |
| Shares Outstanding | — | $133M | $129M | $151M | $133M | $101M | $72M | $62M | $53M | $39M | $33M |
Peer Comparison
Compare DVAX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DVAXYou | $2B | 77.5 | 503.2 | 30.2 | 82.2% | -1.5% | 4.5% | -0.4% | 64.7 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 SIGA | $310M | 13.1 | 6.4 | 7.2 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 VXRT | $133M | 7.9 | 3.3 | 17.6 | 100.0% | 7.6% | 22.3% | 27.1% | 0.3 |
 IBRX | $8B | -19.4 | — | — | 99.3% | -226.0% | — | -235.9% | — |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 GSK | $102B | 6.9 | 8.6 | 13.2 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 SNY | $102B | 18.2 | 10.8 | 10.0 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 MRNA | $25B | -8.8 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
DVAX — Frequently Asked Questions
Quick answers to the most common questions about buying DVAX stock.
What is Dynavax Technologies Corporation's P/E ratio?
Dynavax Technologies Corporation's current P/E ratio is 77.5x. The historical average is 31.3x. This places it at the 100th percentile of its historical range.
What is Dynavax Technologies Corporation's EV/EBITDA?
Dynavax Technologies Corporation's current EV/EBITDA is 503.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 8.8x.
What is Dynavax Technologies Corporation's ROE?
Dynavax Technologies Corporation's return on equity (ROE) is 4.5%. The historical average is -92.2%.
Is DVAX stock overvalued?
Based on historical data, Dynavax Technologies Corporation is trading at a P/E of 77.5x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Dynavax Technologies Corporation's profit margins?
Dynavax Technologies Corporation has 82.2% gross margin and -1.5% operating margin.
How much debt does Dynavax Technologies Corporation have?
Dynavax Technologies Corporation's Debt/EBITDA ratio is 64.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.